Development of a peptide-siRNA nanocomplex targeting NF-κB for efficient cartilage delivery (2019)
Sequence: VLTTGLPALISWIRRRHRRHC
| Experiment Id | EXP001700 |
|---|---|
| Paper | Development of a peptide-siRNA nanocomplex targeting NF-κB for efficient cartilage delivery |
| Peptide | p5RHH |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | Formulated analogously to p65 siRNA NP |
| Rna Concentration | Matched to p65 siRNA NP (e.g., 50 nM in cells; 500 nM in explants) |
| Mixing Ratio | Matched to p65 siRNA NP |
| Formulation Format | Self-assembling peptide/siRNA nanocomplex (NP) |
| Formulation Components | p5RHH peptide + non-targeting control siRNA pool; self-assembled NP |
| Size Nm | 55.00 |
| Zeta Mv | 12.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HUVECs; human articular cartilage explants (IL-1β-stimulated) |
| Animal Model | |
| Administration Route | |
| Output Type | negative control |
| Output Value | No suppression of p65 expression (HUVEC WB) and no sustained reduction of phospho-p65 signal in IL-1β-stimulated cartilage explants compared with p65 siRNA NP. |
| Output Units | |
| Output Notes | Used as control NP in cartilage explant experiments across multiple time points (up to 4 weeks culture). |
| Toxicity Notes | Cartilage surface viability unaffected by NP exposure (TUNEL, Fig. S1). |
| Curation Notes |